Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Jay L PatelMehrdad AbediChristopher R CogleHarry P ErbaKathryn FoucarGuillermo Garcia-ManeroDavid L GrinblattRami S KomrokjiSandra E KurtinJaroslaw P MaciejewskiDaniel A PollyeaDennis A RevickiGail J RobozMichael R SavonaBart L ScottMikkael A SekeresDavid P SteensmaMichael A ThompsonElizabeth Dawn FlickPavel KiselevChrystal U LouisMelissa NifeneckerArlene S SwernTracy I GeorgePublished in: International journal of laboratory hematology (2020)
In the Connect® MDS/AML Registry, only 32% of patients with <15% RS underwent SF3B1 testing after the publication of the WHO 2016 classification criteria. There was no change in RS assessment frequency before and after publication, despite the potential impact on diagnostic subtyping and therapy selection, suggesting an unmet need for education to increase testing rates for SF3B1 mutations.